Trial Profile

A retrospective study to evaluate safety and efficacy of Peptide receptor radionuclide therapy (PRRT) with the radiolabeled somatostatin analogue [Lutetium-177-DOTA0 -Tyr3 ]octreotate (177Lu-DOTATATE) in pateints with pancreatic Neuroendocrine Tumors

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Jan 2019 New trial record
18 Dec 2018 Results assessing safety and efficacy of 177Lu-DOTATATE in patients with pancreatic neuroendocrine tumors, published in the Journal of Clinical Endocrinology and Metabolism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com